Actively Recruiting
First-in-human Study of Orally Administered KT-579 in Healthy Adult Participants
Led by Kymera Therapeutics, Inc. · Updated on 2026-02-27
96
Participants Needed
1
Research Sites
40 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a first-in-human study to evaluate safety and tolerability, pharmacokinetics, and pharmacodynamics of single and multiple dose levels of KT-579 in healthy male and female adult participants.
CONDITIONS
Official Title
First-in-human Study of Orally Administered KT-579 in Healthy Adult Participants
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Participants with weight of at least 50 kg if male or 40 kg if female and BMI between 18.0 and 32.0 kg/m² at Screening
- Participants willing and able to read, understand, and sign informed consent
- Participants willing and able to comply with scheduled visits, treatment plan, lab tests, and study procedures
You will not qualify if you...
- History of significant respiratory, gastrointestinal, renal, hepatic, hematological, lymphatic, endocrinological, neurological, cardiovascular, psychiatric, musculoskeletal, genitourinary, immunological, dermatological, ophthalmological, or connective tissue diseases
- Clinically relevant surgical history that could affect drug pharmacokinetics (except prior appendectomy or cholecystectomy)
- History of alcohol or substance abuse within 2 years
- Any known factor or condition interfering with treatment compliance or study conduct, such as drug or alcohol dependence or psychiatric disease
- Positive test for alcohol or drugs of abuse at Screening or admission
- Acute gastrointestinal symptoms at Screening or admission (e.g., nausea, vomiting, diarrhea, heartburn)
- Abnormal clinical laboratory safety test results at Screening or admission
- Prior receipt of KT-579 in this study
- Use of any investigational drug or device within 30 days or 5 half-lives before dosing
- Male participants who do not agree to refrain from sperm donation until 90 days after last dose
- Participants who do not agree to contraception requirements
- Female participants who are pregnant, lactating, breastfeeding, or plan pregnancy within 30 days after last dose
- Female participants with positive or undetermined pregnancy test at Screening or admission
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Celerion
Lincoln, Nebraska, United States, 68502
Actively Recruiting
Research Team
K
Kymera Medical Director
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
OTHER
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here